A Confirmation Study of Eribulin in Combination With Capecitabine
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Eribulin mesylate|DRUG: Capecitabine
Sponsor: Eisai Limited